Measuring Biology at Scale
Brainalyze is building a patented biochemical-fingerprinting and biological-intelligence platform that converts biological samples into actionable intelligence in under five minutes
Brain health is our focused commercial entry. The larger opportunity spans health, disease, pharmaceutical development, and drug discovery.
Faster and more precise
Current dementia testing methods are costly, inaccessible to many and mostly used for late-stage diagnosis.

Our technology generates ‘optical fingerprints’ from blood samples that are unique to different types of dementia and enable accurate identification of dementia, earlier and faster.
Mission
To build the leading biochemical fingerprinting and disease-intelligence platform for brain health
Vision
To create the disease-intelligence infrastructure and biochemical fingerprint database that enables earlier detection, personalized intervention and population-scale brain-health screening
Proven, simple, and scalable
Refined through NHS trials, our MX-Raman® technology is protected with patents pending in the USA, UK and EU and set to transform how healthcare systems diagnose and treat dementia at scale.
Faster and more precise
Current dementia testing methods are costly, inaccessible to many and mostly used for late-stage diagnosis.

 Our technology generates ‘optical fingerprints’ from blood samples that are unique to different types of dementia and enable accurate identification of dementia, earlier and faster.